Transpercutaneous closure of perimembranous ventricular septal defects by patent ductus occlusion (pdoi)

Abstract

Background: Ventricular septal defect (VSD) is the most frequently occurring congenital cardiac disease, accounts nearly 20-30% of all cases.
 Surgery still the corrective therapy with high success and low complication but having some problems: cardiopulmonary bypass, anesthesia, ICU, sternalitis, chest scar...
 Recently many progress in cardiac intervention applied to treat congenital heart disease especially transpercutaneous VSD closure. currently patients with VSD have other choice to cure safely, effectively and less complication.[1]
 Objectives: To evaluate the long-term rusults from transpercutaneous closure of perimembranous VSD by PDOI.
 Methods: This is the descriptive clinical trial and follow-up.
 Result: 112 patients selected by echocardiography, 107 patients were closed successfully (95.5% success rate), mean time 41 months (37-60) follow-up: occlusive rate 99.1%, no significant complication (no late AVB, worsened TV regurgitation, aortic valve).
 Conclusions: Transpercutaneous closure of perimembranous VSD by PDOI is effective and safe, is suitable for selected PMVSD.